7.2CiteScore
24 daysTime to First Decision

Biologics, Volume 2, Issue 4

December 2022 - 2 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (2)

Select all

Review

7 Citations

8,448 Views

17 Pages

Virus-like Particles (VLPs) as Important Tools for Flavivirus Vaccine Development

Leda R. Castilho,
Nathalia R. Mattos,
Wallace S. Abreu and
Melissa L. E. Gutarra

Biologics2022, 2(4), 226-242;https://doi.org/10.3390/biologics2040018

31 October 2022

Flaviviruses, such as dengue, zika, yellow fever, West Nile, and Japanese encephalitis virus, are RNA viruses belonging to the Flaviviridae family (genus Flavivirus). They represent an important global health concern, since most areas of the world ar...

Full Article

Article

1 Citations

4,404 Views

13 Pages

Real-World Effectiveness and Safety of SDZ-ADL (Adalimumab Biosimilar) in Patients with Psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

Lluís Puig,
Kave Shams,
Fabricio Furlan,
Cristofer Salvati,
Elisa Romero,
Jamie Fan and
Lars Iversen

Biologics2022, 2(4), 213-225;https://doi.org/10.3390/biologics2040017

30 September 2022

SDZ-ADL is a biosimilar of reference adalimumab. Here, the safety and effectiveness data of SDZ-ADL from the British Association of Dermatologists Biologic and Immuno-modulators Register (BADBIR) are reported. In the safety set, data of SDZ-ADL were...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Biologics - ISSN 2673-8449

Imprint

Download Flyer